Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study

被引：0
|
作者：
Thomas, M. [1 ]
Ponce Aix, S. [2 ]
Navarro Mendivil, A. [3 ]
Riera Knorrenschild, J. [4 ]
Schmidt, M. [5 ]
Wiegert, E. [6 ]
Kapp, K. [7 ]
Mauri, C. [8 ]
Domine Gomez, M. [9 ]
Kollmeier, J. [10 ]
Sadjadian, P. [11 ]
Froehling, K-P. [12 ]
Huber, R. M. [13 ]
Wolf, M. [14 ]
机构：
[1] Heidelberg Univ Hosp, Thorac Oncol, German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg TLRC H,Thoraxkli, Heidelberg, Germany
[2] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain
[3] Vall dHebron Univ Hosp, Vall dHebron Inst Res VHIR, Barcelona, Spain
[4] Uniklinikum Giessen & Marburg, Klin Hamatol Onkol & Immunol, Marburg, Germany
[5] Mologen AG, Early & Translat R&D, Berlin, Germany
[6] Mologen AG, Clin Dev, Berlin, Germany
[7] Mologen AG, Translat R&D, Berlin, Germany
[8] UCL, Div Med, London, England
[9] Fdn Jimenez Diaz, Dept Med Oncol, Univ Hosp, Madrid, Spain
[10] Helios Klinikum Emil von Behring GmbH, Lungenklin Heckeshorn, Berlin, Germany
[11] Johannes Weseling Klinikum, Klin Hamatol Onkol & Palliat Med, Minden, Germany
[12] Kath Klinikum Koblenz Montabaur, Klin Innere Med Pneumol, Koblenz, Germany
[13] Univ Munich, LMU Klinikum, Thorac Oncol Ctr Munich, Munich, Germany
[14] Klin Kassel, Med Klin 4, Kassel, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1672P
引用
收藏
页码：599 / 599
页数：1
相关论文
共 50 条
  • [21] Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC)
    Cheng, Ying
    Wang, Jie
    Yu, Yan
    Wang, Qiming
    Yang, Runxiang
    Lv, Dongqing
    Xia, Bing
    Yi, Tienan
    Li, Chong
    Wang, Xicheng
    Zhang, Wei
    Han, Liang
    Liu, Xiaoqing
    Shen, Minjie
    Xu, Jing
    Xue, Peng
    Wang, Weihua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer (ES-SCLC): A tertiary cancer centre experience
    Srivastava, A.
    Shelly, K.
    Lin, F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S46 - S47
  • [23] Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.
    Chen, Lijuan
    Zhao, Yanqiu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Identifying Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Most Likely to Benefit From Intensive Radiation Therapy
    Slotman, B. J.
    Faivre-Finn, C.
    van Tinteren, H.
    Keijser, A.
    Praag, J. O.
    Knegjens, J.
    Hatton, M.
    van Dam, I.
    van der Leest, A.
    Reymen, B.
    Stigt, J.
    Haslett, K.
    Tripathi, D.
    Smit, E.
    Senan, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S153 - S154
  • [25] Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC)
    Paz-Ares, L.
    Johnson, M. L.
    Girard, N.
    Hann, C. L.
    Ahn, M-J.
    Nishio, M.
    Godard, J.
    Laadem, A.
    Yoshizuka, N.
    Qian, M.
    Cheng, B.
    Rudin, C. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1255 - S1256
  • [26] A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).
    Langer, C. J.
    Albert, I.
    Kovacs, P.
    Blakely, L. J.
    Pajkos, G.
    Petrov, P.
    Somfay, A.
    Szczesna, A.
    Zatloukal, P.
    Kazarnowicz, A.
    Moezi, M. M.
    Schreeder, M. T.
    Schnyder, J.
    Berger, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
    Gao, F.
    Zhao, Y.
    Li, X.
    Li, Y.
    Ma, T.
    Li, Q.
    Tang, X.
    Han, X.
    Yi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1069 - S1069
  • [28] Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer
    Zhou, Zheng-tao
    Zhou, Fu-xiang
    Wei, Qing
    Zou, Li-yong
    Qin, Bin-fang
    Peng, Xu-shen
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (04) : 1027 - 1032
  • [29] UPDATED PFS ANALYSIS OF TORIPALIMAB WITH ANLOTINIB AND CHEMOTHERAPY AS FIRST-LINE THERAPY IN PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC)
    Luo, Hao
    Jian, Dan
    Feng, Yan
    Zhong, Li
    Chen, Qian
    Guan, Wei
    Zhang, Shiheng
    Luo, Jiamin
    Yang, Xueqin
    Gong, Kan
    Xiong, Yanli
    Li, Mengxia
    Xu, Mingfang
    Pu, Yu
    Zhao, Liang
    Qian, Chengyuan
    Dai, Nan
    Wang, Dong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A490 - A490
  • [30] Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer
    Zheng-tao Zhou
    Fu-xiang Zhou
    Qing Wei
    Li-yong Zou
    Bin-fang Qin
    Xu-shen Peng
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1027 - 1032
12345